Ana de Barros, PhD,  managing science editor—

Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.

Articles by Ana de Barros

APDA Partners with Smart Patients to Support Parkinson’s Online Community

The American Parkinson Disease Association (APDA) is collaborating with Smart Patients — an online community connecting Parkinson’s patients and their families — to extend APDA’s resources to help people living with the disease. Smart Patients provides resources so people can have the latest information related to their condition, share their questions and…

Michael J. Fox Foundation Awards 3 Trial Centers $125,000 in New Parkinson’s Trial Recruitment Program

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is giving three clinical trial centers a $125,000 incentive to increase accessibility and volunteer enrollment in Parkinson’s disease (PD) studies as part of its new Parkinson’s Disease Trial Recruitment Innovation (PD-TRI) program. The centers – Barrow Neurological Institute in…

Trial Data on Rytary and Off Episodes in Advanced Parkinson’s Being Given at AAN

Impax Laboratories is presenting data on its approved Parkinson’s disease treatment, Rytary, as well as findings in a clinical trial assessing a version of this extended-release carbidopa and levodopa mixture (IPX203) in people with advanced disease symptoms, including possible improvements in daily activities and quality of life. The presentations began Sunday and run…

Adamas to Give Presentations on Treatment for Involuntary Muscle Movements in Parkinson’s

Adamas Pharmaceuticals will make two presentations in Boston this month on ADS-5102 as a treatment for involuntary muscle movements associated with Parkinson’s disease. ADS-5102, a high-dose amantadine therapy, decreases the duration, intensity and debility of the muscle movements, clinical trials have shown. The problems, which range from slight hand tremors to uncontrollable upper…

MJFF Grant Will Support Mission Therapeutics’ Test of Novel USP30 Therapy in Parkinson’s Models

British pharmaceutical firm Mission Therapeutics will test its potent, selective USP30-targeted inhibitors in stem cell-derived Parkinson’s disease models, as part of research funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). Cells maintain healthy mitochondria — the cell’s power generators — by degrading damaged mitochondria in a process known as mitophagy. Defective…

Zambon, Valeo Collaborate to Bring Xadago to Canadian Parkinson’s Patients

Italian pharmaceutical conglomerate Zambon has partnered with Montreal-based Valeo Pharma to bring Xadago (safinamide) to Canada, where 100,000 patients living with Parkinson’s disease (PD) will now have access to this recently approved drug. Xadago was developed by Italy’s Newron Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA)…